Clinical Trial Update: Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating imatinib mesylate with or without bevacizumab in metastatic or unresectable gastrointestinal stromal tumor was terminated with posted r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Bevacizumab (bevacizumab)
• Imatinib mesylate (Imatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Gastrointestinal Stromal Tumor | Phase 3 | Status: TERMINATED | Results posted: 2017-09-14